We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Selenium Linked to Bladder Cancer in Certain Population Groups

By LabMedica International staff writers
Posted on 12 Jan 2009
Results obtained from a large comparative study showed an inverse relationship between levels of selenium, a trace mineral found in grains, nuts, and meats, and incidence of bladder cancer in certain population groups.

Investigators at Dartmouth Medical School (Hanover, NH, USA) compared toenail selenium levels in 767 bladder cancer patients to the levels of 1,108 individuals from the general population. More...
They used logistic regression analyses to generate odds ratios (OR) and 95% confidence intervals (95% CI) while controlling age, sex, and pack-years of smoking. In addition, they conducted separate analyses according to the intensity of p53 immunohistochemical staining of the tumor.

Results published in the January 2009 issue of the journal Cancer Prevention Research revealed that there was no overall inverse relationship between selenium concentration and incidence of bladder cancer. However, within specific subgroups there were inverse associations. These included moderate smokers, women, and those with p53-positive cancers. These groups all had higher rates of bladder cancer while manifesting lower toenail concentrations of selenium. Increased selenium concentrations in these groups were linked to lower incidence of cancer.

"Ultimately, if it is true that selenium can prevent a certain subset of individuals, like women, from developing bladder cancer, or prevent certain types of tumors, such as those evolving through the p53 pathway, from developing, it gives us clues about how the tumors could be prevented in the future and potentially lead to chemopreventive efforts,” said senior author Dr. Margaret R. Karagas, professor of community and family medicine at Dartmouth Medical School. "There are different pathways by which bladder cancer evolves and it is thought that one of the major pathways involves alterations in the p53 gene. Bladder cancers stemming from these alternations are associated with more advanced disease.”

Related Links:
Dartmouth Medical School



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.